Lilly Arthritis Drug Shows Promising Results

ThinkstockPhotos-463594335

INDIANAPOLIS, Ind. – Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an…